Business

Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the appointment of Tomas J. Philipson, PhD as a Strategic Advisor.

articleSoligenix, Inc.September 23, 202515/company/soligenix-inc/news/soligenix-announces-appointment-former-white-113000460
Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor

About this update from Soligenix, Inc.

[{"type":"text","content":"Contributing Broad Business and Government Affairs Expertise and Network ","length":72,"tagName":"p","attribs":{}},{"type":"text","content":"PRINCETON, N.J., Sept. 23, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the appointment of Tomas J. Philipson, PhD as a Strategic Advisor.","length":340,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Soligenix, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Soligenix, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":112,"url":"https://media.zenfs.com/en/prnewswire.com/85ba4191e64f574a13cd0c133f4a3048"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/0bSTAeYRTNnLNEjUJiiRHg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE5NztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/85ba4191e64f574a13cd0c133f4a3048","width":400,"height":112}},"href":"https://mma.prnewswire.com/media/1768046/Soligenix_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Dr. Philipson is considered an expert in United States (U.S.) economic policy, particularly health care policy, and frequently appears on major media outlets, including Forbes, The Economist, The Wall Street Journal, The New York Times, CNN, BBC, CBS, ABC, CNBC, Fox News, Fox Business, Newsmax, Yahoo Finance, American Voice, Bloomberg, and CSPAN. He currently serves as Managing Partner of the venture capital firm MEDA Ventures; serves on several corporate boards; and has co-founded several companies, including Precision Health Economics LLC, with an exit in 2015 (currently owned by Blackstone). His government service includes a full-time position as vice chairman and acting chairman of President Trump's White House Council of Economic Advisers from 2017 to 2020. He previously served as a senior economic adviser to the head of the U.S. Food and Drug Administration (FDA) and a senior economic advisor to the head of the Centers for Medicare and Medicaid Services (CMS). Dr. Philipson was appointed to the Key Indicator Commission by the Speaker of the House of Representatives in 2012. He was a scientific advisor to the House of Representatives initiative 21st Century Cures in 201...

More updates from Soligenix, Inc.

Tomas J. PhilipsonSoligenix, Inc.rare diseasesEconomic ResearchHealth EconomicsPhase 3 clinical trialHouse of RepresentativesPhD in EconomicsThe Wall Street JournalFood and Drug Administrationclinical study